use of clomid in control of DMPA bleeding

Clomiphene citrate as a new modality in management of bleeding with depomedroxyprogesterone acetate (DMPA)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201801002953256

Enrollment

250

Registered

2018-01-09

Start date

2017-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility-female contraceptive bleeding

Interventions

clomiphene citrate

control gprou

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: any woman at any age, any weight, any parity who are DMPA user for any period who complaining of irregular uterine bleeding.

Exclusion criteria

Exclusion criteria: any general causes of vaginal bleeding as known bleeding tendency abnormal coagulation profile anticoagulant drugs users or hepatic patients

Design outcomes

Primary

Measure	Time frame
stopping of bleeding	—

Secondary

Measure	Time frame
endometrial thickness , continuity of bleeding stoppage any side effects	—

Countries

Egypt

Contacts

Public Contactahmed samir sanad

assistant professor of obstetrics and gynecology faculty of medicine minia university egypt

asasanad@hotmail.com002/01000222994

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026